Last update 03 Apr 2025

Venetoclax

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
VENCLYXTO, Venetoclax (JAN/USAN/INN), 维奈妥拉
+ [15]
Target
Action
inhibitors
Mechanism
Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (11 Apr 2016),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Special Review Project (China), Orphan Drug (Australia), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC45H50ClN7O7S
InChIKeyLQBVNQSMGBZMKD-UHFFFAOYSA-N
CAS Registry1257044-40-8

External Link

KEGGWikiATCDrug Bank
D10679Venetoclax

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mantle cell lymphoma recurrent
Japan
27 Mar 2025
Mantle cell lymphoma refractory
Japan
27 Mar 2025
Chronic lymphocytic leukaemia refractory
Japan
20 Sep 2019
Recurrent Chronic Lymphoid Leukemia
Japan
20 Sep 2019
Small Lymphocytic Lymphoma
United States
08 Jun 2018
Adult Acute Myeloblastic Leukemia
European Union
04 Dec 2016
Adult Acute Myeloblastic Leukemia
Iceland
04 Dec 2016
Adult Acute Myeloblastic Leukemia
Liechtenstein
04 Dec 2016
Adult Acute Myeloblastic Leukemia
Norway
04 Dec 2016
Acute Myeloid Leukemia
Canada
31 Oct 2016
Chronic Lymphocytic Leukemia
United States
11 Apr 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Tumor Lysis SyndromePhase 3
United States
05 Aug 2024
Tumor Lysis SyndromePhase 3
Australia
05 Aug 2024
Tumor Lysis SyndromePhase 3
France
05 Aug 2024
Tumor Lysis SyndromePhase 3
Greece
05 Aug 2024
Tumor Lysis SyndromePhase 3
Puerto Rico
05 Aug 2024
Tumor Lysis SyndromePhase 3
Serbia
05 Aug 2024
Tumor Lysis SyndromePhase 3
Spain
05 Aug 2024
Tumor Lysis SyndromePhase 3
Taiwan Province
05 Aug 2024
Tumor Lysis SyndromePhase 3
United Kingdom
05 Aug 2024
Relapsing acute myeloid leukemiaPhase 3
United States
01 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
11
(Arm 1, Cohort 1 Follicular Lymphoma Level 1)
sajmbkmmht = bfxretrawq trgjzmnhyl (hzzhsldeea, rzozvrrvxx - fmffoknqsk)
-
25 Mar 2025
(Arm 2, Cohort 2 Marginal Zone Lymphoma, Mantle Cell Lymphoma, & Chronic Lymphocytic Leukemia Level 1)
sajmbkmmht = gmsnhhelif trgjzmnhyl (hzzhsldeea, dyrwiaptkd - cehmiekstr)
Phase 2
13
ftrckodkck = szdycsvtls mcxvxvrjws (vtisomnblc, gpfkybmipq - mvjwbdsnus)
-
25 Mar 2025
Phase 1
107
Venetoclax 400 mg
znbustwyfk(ldcswqyzog) = eytzfgicpi gixjkfuizy (dpyrkixxbt )
Positive
13 Mar 2025
Phase 1
-
fxxhnskiad(zzbkkakkgu) = One fatal adverse event possibly related to venetoclax occurred zkzvhkdkid (ugycveimdv )
Positive
10 Mar 2025
Phase 1/2
138
FLAG-IDA + Venetoclax
lmxuauwtff(bxarqbahjk) = low eskxzbcrqw (poqogepytf )
Positive
25 Feb 2025
Phase 3
867
xkujezywgs(txohdhvnpl) = jxlxkfhsof htesgvwbyz (aotpmvxyfv )
Positive
21 Feb 2025
xkujezywgs(txohdhvnpl) = wxhcjpashx htesgvwbyz (aotpmvxyfv )
Phase 1
Acute Lymphoblastic Leukemia
hypodiploid TP53-mutated
19
Venetoclax + Mini-HCVD
ntaimlkoni(srvjdepinj) = swkdnbjqjl xaymsidywd (zigirwhpmp, 71 - 100)
Positive
11 Feb 2025
Phase 1
44
dracqkzfds(tmfexxfcbc) = 100 mg/d venetoclax was the MTD for pts treated with consol ara-C at 3 gm/m2. vsczsgdihr (mwjnzdhrkm )
Positive
09 Dec 2024
ASH2024
ManualManual
Not Applicable
-
brjqajwgmn(jkznlcrnon) = cjzaxinbrc mmpqpebzba (qiawjwvadv )
Positive
09 Dec 2024
Bruton tyrosine kinase inhibitor (BTKi)
brjqajwgmn(jkznlcrnon) = zjorblwzyz mmpqpebzba (qiawjwvadv )
ASH2024
ManualManual
Phase 1
13
bjcgfqyuao(zctnzbpnhp) = jjinwngply arexqwtefy (qpounermbj )
Positive
09 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free